Metamizole Abz (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins—compounds that mediate pain and fever. This inhibition lowers the perception of pain and helps reset the hypothalamic temperature set‑point, producing antipyretic action.

The appropriate dose of Metamizole is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens vary, and the prescriber will tailor the amount and frequency to achieve optimal therapeutic effect.

Safety data for Metamizole in pregnancy and lactation are limited. It is generally classified as contraindicated or used only when the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Metamizole Abz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole provides analgesic and antipyretic effects similar to NSAIDs but has a distinct safety profile. While NSAIDs commonly cause gastrointestinal irritation and affect platelet function, Metamizole’s primary concern is rare but serious blood dyscrasias like agranulocytosis. Choice of therapy depends on patient risk factors and clinical judgment.

Metamizole should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Metamizole is administered orally, typically as a tablet or liquid preparation, according to the prescriber’s instructions. The medication should be taken with or without food as directed, and the full course should be completed unless advised otherwise by a healthcare professional.

The most serious risks include agranulocytosis, a severe drop in neutrophil count that can lead to life‑threatening infections, as well as severe skin reactions such as Stevens‑Johnson syndrome and anaphylaxis. Patients should be monitored for signs of infection, rash, or allergic reactions and seek immediate medical attention if they occur.

Metamizole should not be used by individuals with known hypersensitivity to the drug or other pyrazolones, patients with a history of agranulocytosis, and those receiving other myelotoxic agents unless closely monitored. Caution is also advised in patients with severe liver or kidney impairment.